Abstract
The current level of evidence for immunotherapy in previously untreated microsatellite unstable metastatic colorectal cancer is based on recent pieces of evidence of few studies that demonstrated durable response and clinical benefit, in terms of objective response rate, disease control rate, and progression-free survival in this subgroup of patients. On the basis of combinatorial immunotherapy with nivolumab plus ipilimumab, we report the exceptional case of a complete pathological response in a 21-year-old woman presenting a clinically aggressive stage IV colorectal cancer with massive nodal and liver involvement. Extensive molecular analyses based on whole genome next-generation DNA sequencing, RNA sequencing, fluorescent multiplex immunohistochemistry, and flow cytometry provided a detailed description of tumoral and immunological characteristics of this noteworthy clinical case.
Introduction
Colorectal cancer (CRC) is the fourth cause of cancer-related deaths worldwide (1). Deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) occurs in about 5% of metastatic CRC (mCRC) (2). The optimal first-line treatment regimen in mCRC has been represented by combining chemotherapy and anti-vascular endothelial growth factor or anti-epidermal growth factor receptor antibodies. However, its clinical benefit is limited with a median overall survival (OS) of approximately 30 months (3, 4). In the last 2 years, practice-changing results of two studies, KEYNOTE-177 and CHECKMATE-142, validated immunotherapy in previously untreated microsatellite unstable (dMMR/MSI-H) mCRC. The first trial demonstrated durable clinical benefits of pembrolizumab in terms of progression-free survival (PFS) compared with standard chemotherapy in patients with dMMR/MSI-H mCRC (16.5 months vs. 8.2 months; HR, 0.59; 95% CI, 0.45 to 0.79) and a significant increase in objective response rate (ORR). The second study confirmed the benefits of immunotherapy in this subgroup and identified a synergy from the dual blockade of Programmed cell death-1 PD-1 (PD-1) and Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), and nivolumab and ipilimumab. The primary endpoint ORR was 69% (95% CI, 53 to 82) with a disease control rate (DCR) of 84% (95% CI, 70.5 to 93.5) and a radiological complete response rate of 13% at median follow-up of 29.0 months (5–7).
Here, we describe an exceptional case of a clinically complex MSI-H stage IV CRC associated with Lynch syndrome. The patient received exclusively nivolumab plus ipilimumab as upfront treatment and obtained an impressive response. She underwent surgical resection of radiological residual disease with the confirmation of a pathological complete response (pCR), a very rare event with standard chemotherapies (8).
Case report
In March 2017, a 21-year-old woman with no significant past medical or familiar history was referred to a Community Hospital after a 3-month history of diarrhea, progressive worsening of asthenia (up to grade 3), and 13% body weight loss in 8 weeks. Visit and laboratory tests showed clinical deterioration [Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) = 3], hyperpyrexia, increase in white blood count, and thrombocytosis. Abdomen computed tomography (CT) and magnetic resonance imaging (MRI) showed a large neoplastic mass involving the ascending colon, the right colic flexure (maximum diameter of 13 cm) and the liver, suspected infiltration of the head of the pancreas and the duodenum, extensive abdominal lymphadenopathies, and ascites. Moreover, colonic perforation was suspected due to perilesional fluid collection (Figure 1A).
Figure 1
The patient underwent an urgent right colonic resection. Histology evidenced a poorly differentiated colonic adenocarcinoma (CRC), pT4a N2b based on TNM classification with macroscopic residual of disease (Figure 2C). The carcinoembrionyc antigen (CEA) level was determined at the diagnosis and subsequently at CT scan evaluations; it remained within normal limits during all the history of the disease.
DNA sequencing, performed subsequently at our center by mass spectrometry (with Kit Myriapod Colon status, Diatech Pharmacogenetics – MassArray analyzer), and immunohistochemistry (IHC) revealed a RAS/BRAF wild-type status, a high tumor mutational burden (TMB), with more than 1,700 somatic non-synonymous variants, and an estimated exonic mutation rate of 68.3 mutations/megabase.
The determination of microsatellite instability was evaluated by multiplex amplification with fluorescent primers and subsequent DNA fragment analysis on automated sequencer (Titano MSI kit CE-IVD Diatech Pharmacogenetics). It confirmed a germline non-sense mutation in MLH1 gene with a complete loss expression of MLH1 and PMS2 (mismatch repair deficiency), and Lynch syndrome was diagnosed.
RNA sequencing (RNAseq) data were used to assess potential overexpression of key immune modulators and also to assign the patient to one of the four colorectal consensus molecular subtypes (CMSs). The patient’s CMS was predicted as CMS4 (9), whereas RNAseq of immunotherapy-related genes revealed a high expression of Indoleamine 2,3-Dioxygenase 1 (IDO1) only.
The post-operative course was complicated by jaundice and hyperbilirubinemia (up to 8 mg/dl); hepatic ultrasound showed bile duct dilatation due to duodenal compression, which required insertion of a biliary metallic stent. After 28 days, she was dismissed with a mild improvement of general conditions and referred to our Comprehensive Cancer Center. Two days later, worsening of clinical conditions, hyperpyrexia (up to 39°C), and persistent alteration of liver function required immediate hospitalization. A re-staging CT scan confirmed large liver metastases, with diameter up to 12.2 cm, associated to hilar and abdominal lymphadenopathy, and a 7-cm abscess associated with cancer in S4 (Figure 2A).
Figure 2
An endoscopic retrograde cholangiopancreatography evidenced the partial obstruction of the biliary metallic stent, which required the insertion of an additional self-expandable metallic stent. Although liver function progressively improved, clinical conditions remained extremely unstable with recurrent febrile episodes, elevation of inflammatory markers, and a high risk of septic shock.
A multidisciplinary team extensively discussed the options of: i) a surgical exploration, ii) standard systemic treatment, or iii) opportunity for molecularly driven clinical trial.
Over a 48-h observation period, fever resolved and general conditions and liver functions improved, and she was enrolled in a phase 2 clinical trial (5) and received nivolumab (3 mg/kg q2w) plus ipilimumab (1 mg/kg q6w).
On 28 April 2017, nivolumab plus ipilimumab treatment was started. After 2 h from the administration, the patient had a progressive pain worsening in right hypochondrium and a sudden drop of hemoglobin. An ultrasound revealed bleeding of liver metastases requiring radiological embolization. After a few hours, the patient had hyperpyrexia and shivering, increase of inflammation markers, and hypotension. On 30 April 2017, the patient was transferred to the intensive care unit; blood cultures grew Enterococcus faecium, and meropenem and daptomycin were started, with a rapid general improvement and defervescence. At day 14 from the first administration, the patient received the second planned dose. A follow-up ultrasound showed a major shrinkage of the hepatic abscess. Thus, she was discharged, and the following cycles were planned as an outpatient.
General conditions rapidly improved over the next 4 weeks. A CT scan after the first cycle showed an initial reduction of all target lesions (Figure 1B). A massive shrinkage and the best response were achieved after six cycles, being maintained thereafter up to the completion of 9 cycles over a 12-month period, without any toxicity or delay (Figures 1C, 2B).
On the basis of clinical course and multidisciplinary discussion, a surgical abdominal exploration was decided without evidence of extrahepatic involvement, whereas an intraoperative ultrasound suspected S4b-S5 metastatic residual disease. Consequently, an anatomic liver resection of en bloc S4b-S5, cholecystectomy, and hilar lymphadenectomy were performed. The post-operative course was uneventful, and the patient was discharged in post-operative day 6.
Liver lesion (LL) histology evidenced a pCR with fibrous tissue, necrosis and lympho-histiocytic inflammation, and no residual tumor cells (Figure 2D). Sample was graded as tumor regression score equal to 1 (10, 11).
Fluorescent multiplex IHC (mIHC) was performed to characterize lymphocyte population and immune checkpoint expression. mIHC analysis was carried out on of formalin-fixed paraffin-embedded tissue samples from primary tumor (PT) and secondary LL, whose cell composition is described in Figures 2E–J. According to histology, no cytokeratin+ tumor cells were detected in LL (Figures 2F, H, J), whereas infiltrating immune cells were increased at least five-folds compared to PT (Figures 2I–K). In particular, B cells increased more than 200-folds (Figures 2I–K) and appeared organized in agglomerates resembling tertiary lymphoid structures (Supplementary Figure S1). Flow cytometry analysis of total leukocytes infiltrating the fresh lesion revealed that the percentages of T- and B cells were higher than in the reference group (Figures 2L, M, S2), which consisted of liver metastases (n=7) collected from additional CRC patients treated with standard chemotherapy (Supplementary Table 1). Moreover, peripheral blood T and B cells increased after treatment start (Supplementary Figure S3).
A deeper assessment of lymphocyte populations disclosed a strong prevalence of CD8+ T cells in PT (CD8+/CD4+ ratio = 3.2) that was partially maintained in LL (CD8+/CD4+ ratio = 2) (Figures 3A–C). These data were confirmed in the fresh sample (CD8+/CD4+ ratio = 1.4) and completely differed from the reference group (CD8+/CD4+ ratio = 0.38; Figure 3D). Notably, in the PT, almost all T cells stained positive for granzyme B, irrespective of the subset phenotype (Figures 3A, C). This activation status persisted in LL (Figures 3B, C), where most of infiltrating T cells showed an effector-memory phenotype with a minority being terminally differentiated (Supplementary Figure S4). Peripheral blood T cells disclosed an expression peak of the IL-7 receptor (IL-7Rα) just after treatment start (Figure 3E), suggesting the induction of a memory pool subsequently observed in the LL. T-regulatory cells were already detected in PT and increased 20-folds in LL (Figure 3F). They were higher than in the reference group (Figure 3G).
Figure 3
Moreover, mIHC showed that 25% of T cells expressed PD-1 in PT, most of them being also TIM-3+ and LAG-3+ (Figures 4A, C). These percentages remained essentially unchanged in LL after treatment (Figures 4B, C). Cytometry data of LL additionally demonstrated that the percentage of PD-1+ cells within either CD4+ or CD8+ populations was much lower than in the reference group (Figure 4D). In both PT and LL, intensity of PD-1 expression in T cells was low (Supplementary Figure S5 and Figure 4E) and differed clearly from the reference group (Figure 4F). PD-1 expression was appreciable in peripheral blood T cells before treatment and decreased after immunotherapy start (Figure 4G). A small fraction of cancer cells expressed PD-L1 in PT (Figures 4A, H). Putative PD-L1+ macrophages were organized in rare agglomerates in the PT, whereas they were scattered and highly increased in LL (Supplementary Figure S6 and Figures 4B, H).
Figure 4
At the time of writing, 4 years since surgery, the patient is in excellent clinical conditions. She received immunotherapy until the end of 2018. A re-staging CT scan was performed every 8 weeks for 2 years and then every 16 weeks without evidence of disease recurrence. She lives a completely normal life without significant consequences related to surgery or immunotherapy. Regular oncologic follow-up and Lynch syndrome surveillance are still ongoing.
Discussion
In this case report, we describe the case of a very young patient with a Lynch syndrome with MSI-H stage IV mCRC. The patient received exclusively nivolumab plus ipilimumab as upfront treatment within a phase 2 study and obtained an impressive and durable response, in line with clinical data of the trial CheckMate-142 (6, 7) and particularly with results obtained in a previously untreated patient’ cohort receiving immunotherapy combination (5).
In this regard, Chalabi et al. presented a study with a single-dose of neoadjuvant ipilimumab plus nivolumab in early-stage CRC, resulting in 100% major pathological response and 57% pCR in a total of seven MSI-H tumors (12). Moreover, very recently, Cercek and colleagues reported that single check point blockade in mismatch repair–deficient II or III rectal cancer reached 100% of clinical response rate (13). Although the sample size and the follow-up are limited, this amazing result and the growing pieces of evidence confirm the high efficacy of immunotherapy as upfront therapy and support its role even in the neoadjuvant setting.
From a clinical perspective, this case remarks the following open issues: a) whether immunotherapy should be always offered upfront to all patients with MSI-H; b) which is the optimal treatment duration; c) how to properly interpret radiological data, d) which could be reliable surrogate markers of a pCR; and therefore e) whether surgery on residual disease is really necessary.
To date, a large part of patient with advanced MSI-H mCRC are not candidate to radical surgery, and data about pathological response are limited. Our case provided a rare opportunity for running a parallel extensive translational study on primary and post-treatment samples. MSI-H status and high TMB support the high immunogenic features of this tumor and predicted sensitivity to immunotherapy (14, 15). On the other hand, a high expression of IDO1 and CMS4 subtype is somewhat unexpected, with these features being advocated as putative mechanisms of immune resistance (16). Moreover, CMS4 is not typical of MSI-H and BRAF wild-type tumors, which normally belong to CMS1 (9). Only a fraction of MSI-H CRCs is associated to Lynch syndrome, but preliminary data on their response to immunotherapy are based on small subgroup analyses and do not definitely clarify whether they benefit more than sporadic tumors (5, 6).
Tumor neoantigens generated by the high TMB likely induced a strong immune response even before immunotherapy start. Indeed, PT disclosed a strong prevalence of CD8+ over CD4+ T cells with both subsets having an activated and cytotoxic phenotype. Such infiltrating immune cells largely increased in post-treatment LL as compared to PT, with a partially maintained CD8+/CD4+ ratio but the acquisition of an effector-memory phenotype. With regard to B cells, they not only strongly increased in LL but organized in agglomerates resembling tertiary lymphoid structures.
Finally, also, T-regulatory cells, already detected in PT, increased in LL.
All these features are strongly reminiscent for a powerful boost of a pre-existing immune response. Accordingly, kinetics analysis of circulating cells confirmed that immunotherapy unleashed the patient’s immune response, especially during the first 6–9 months of therapy.
In fact, the raising of T and B cells and the rapid increase of IL-7Rα-expressing T cells indicated the development and the maintenance of memory pools (17, 18) and anticipated the immune features found in the LL.
The fact that T and B cells were more represented in LL together with a cytotoxic phenotype of both CD4+ and CD8+ cells and a prevalence of CD8+ T-cells are all features associated with a better prognosis in CRC (19–21). Furthermore, the presence of tertiary lymphoid structures is another marker associated with a favorable clinical prognosis not only in CRC (22–24). Notwithstanding, the CD4+ and CD8+ T cells infiltrating the LL appeared poorly proliferating and had a moderate expression of IL-7Rα (data not shown), whose downregulation prepares cells for death during the resolution of the immune response (25). In the LL, we also observed more suppressive Treg and PD-L1+ macrophages. Collectively, these data are not only the signature of an immune response that is still operative and specialized, but also the mark of resolution after tumor eradication.
Regarding immune checkpoint expression, the percentage of T cells expressing PD-1 in PT remained essentially unchanged in LL after treatment, and this, in turn, appeared lower than in the reference group. Moreover, PD-1 was present at a low intensity on infiltrating T cells, and its expression decreased in peripheral blood T cells during treatment, globally suggesting a therapeutic response (26). Similarly, the slight expression of PD-L1 in PT can be considered another favorable prognostic feature, although still debated (27–29). Despite the role of LAG-3 and TIM-3 is still open to discussion (30–34), these molecules may not be considered as independent and isolated immune inhibitors but rather as co-indicators together with PD-1 of a still active inflammatory response where T cells are activated to exert their antitumor activity, and a part of them is progressively turning off and becoming exhausted. Therefore, the co-expression of PD-1, LAG-3, and TIM-3 on T cells suggests that additional combinatory immune checkpoint blockade therapies could be required in poorly responding cases (35, 36).
In summary, we present an exceptional and clinical complex case of a patient with MSI-H mCRC with a 4-year complete durable response after receiving exclusively immunotherapy agents, i.e., the PD-1 inhibitor nivolumab and the CTLA-4 inhibitor ipilimumab, without any relevant adverse event. In this case, the high efficacy of immunotherapy combination in MSI-H mCRC also relied, from a pathological point of view, on the confirmation of a pCR, a rare event with standard therapies that is associated to long-term survival or even the chance for cure. Nevertheless, the extensive molecular analysis and immunoprofiling carried out provided additional dynamical insights about the evolution of an immune response, which ultimately leads to a therapeutic success. In addition, the characterization of the immune contexture in the primitive lesions, like the expression/co-expression of checkpoint inhibitors, can offer important predictive hints about the potential benefit of combinatorial immune checkpoint blockade therapies to overcome resistance in patients with poor response to primary treatments.
Overall, further studies are required to validate the current immunological conclusions and to identify patients in which surgery could be an option despite stage of disease or, conversely, when it could be avoided in the presence of complete response after immunotherapy treatment.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.
Ethics statement
Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
Author contributions
SL, FB, FL, VZ, KC, and CG as medical doctors and Medical Oncology specialist were in charge of patient medical treatment; EG and UC performed surgical procedures; MF, ADT, and VA performed histopathology, immunophenotype and molecular assessment; GR and ARa performed radiological assessment; AT performed mIHC analysis; SDS and ADP performed cytofluorimetric analysis; SDS, AT, and ADP supervised and managed the data generation and data analysis; FC and SB performed the genomic and transcriptomic sequencing and the proteomic analyses; ARo contributed to the analysis and interpretation of the data and reviewed all drafts of the manuscript; all authors contribute to manuscript preparation, writing, revision and fully approved the content.
Funding
This work has been supported by 5x1000 Italian Health Ministry’s Research Program to VZ (Cancer genomics and immunotherapy in the era of big data, phase 2 - 5x1000, reference year 2015).
Conflict of interest
VZ declares a conflict of interest: consulting or Advisory Role: Bristol-Myers Squibb, MSD, Eisai, ITALFARMACO; Speakers Bureau: Roche, Bristol-Myers Squibb, Astellas Pharma, SERVIER, AstraZeneca, MSD, JANSEN, IPSEN; Research Funding: Bayer, Roche, Lilly, Astra Zeneca, BMS, Ipsen, Astellas Pharma. SL reports personal fees as speaker bureau or advisor from Amgen, Merck Serono, Lilly, Astra Zeneca, Incyte, Daiichi-Sankyo, Bristol-Myers Squibb, Servier, MSD, Roche, Bristol-Myers Squibb, Pierre-Fabre, GSK and received research grants from Amgen, Merck Serono, Bayer, Roche, Lilly, Astra Zeneca, Bristol-Myers Squibb, unrelated to the current work.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.964219/full#supplementary-material
References
1
BrayFFerlayJSoerjomataramISiegelRLTorreLAJemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2018) 68(6):394–424. doi: 10.3322/caac.21492
2
SinicropeFASargentDJ. Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clin Cancer Res (2012) 18(6):1506–12. doi: 10.1158/1078-0432.CCR-11-1469
3
BensonABVenookAPAl-HawaryMMArainMAChenYJCiomborKKet al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw (2021) 19(3):329–59. doi: 10.6004/jnccn.2021.0012
4
LoupakisFCremoliniCMasiGLonardiSZagonelVSalvatoreLet al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med (2014) 371(17):1609–18. doi: 10.1056/NEJMoa1403108
5
LenzHJVan CutsemELuisa LimonMWongKYMHendliszAAgliettaMet al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-High/Mismatch repair-deficient metastatic colorectal cancer: The phase II CheckMate 142 study. J Clin Oncol (2022) 40(2):161–70. doi: 10.1200/JCO.21.01015
6
OvermanMJLonardiSWongKYMLenzHJGelsominoFAgliettaMet al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-Deficient/Microsatellite instability-high metastatic colorectal cancer. J Clin Oncol (2018) 36(8):773–9. doi: 10.1200/JCO.2017.76.9901
7
AndréTShiuKKKimTWJensenBVJensenLHPuntCet al. Pembrolizumab in microsatellite-Instability-High advanced colorectal cancer. N Engl J Med (2020) 383(23):2207–18. doi: 10.1056/NEJMoa2017699
8
GruenbergerTBridgewaterJChauIGarcía AlfonsoPRivoireMMudanSet al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol (2015) 26(4):702–8. doi: 10.1093/annonc/mdu580
9
GuinneyJDienstmannRWangXDe ReynièsASchlickerASonesonCet al. The consensus molecular subtypes of colorectal cancer. Nat Med (2015) 21(11):1350–6. doi: 10.1038/nm.3967
10
BlazerDGKishiYMaruDMKopetzSChunYSOvermanMJet al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol (2008) 26(33):5344–51. doi: 10.1200/JCO.2008.17.5299
11
Rubbia-BrandtLGiostraEBrezaultCRothADAndresAAudardVet al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol (2007) 18(2):299–304. doi: 10.1093/annonc/mdl386
12
ChalabiMFanchiLFDijkstraKKVan den BergJGAalbersAGSikorskaKet al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med (2020) 26(4):566–76. doi: 10.1038/s41591-020-0805-8
13
CercekALumishMSinopoliJWeissJShiaJLamendola-EsselMet al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med (2022) 386(25):2363–76. doi: 10.1056/NEJMoa2201445
14
RizviNAHellmannMDSnyderAKvistborgPMakarovVHavelJJet al. Cancer immunology. mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 348(6230):124–8. doi: 10.1126/science.aaa1348
15
LeDTUramJNWangHBartlettBRKemberlingHEyringADet al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med (2015) 372(26):2509–20. doi: 10.1056/NEJMoa1500596
16
PlattenMvon Knebel DoeberitzNOezenIWickWOchsK. Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors. Front Immunol (2014) 5:673. doi: 10.3389/fimmu.2014.00673
17
SchlunsKSKieperWCJamesonSCLefrançoisL. Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo. Nat Immunol (2000) 1(5):426–32. doi: 10.1038/80868
18
SeddonBTomlinsonPZamoyskaR. Interleukin 7 and T cell receptor signals regulate homeostasis of CD4 memory cells. Nat Immunol (2003) 4(7):680–6. doi: 10.1038/ni946
19
BerntssonJSvenssonMCLeanderssonKNodinBMickePLarssonAHet al. The clinical impact of tumour-infiltrating lymphocytes in colorectal cancer differs by anatomical subsite: A cohort study. Int J Cancer (2017) 141(8):1654–66. doi: 10.1002/ijc.30869
20
BerntssonJNodinBEberhardJMickePJirströmK. Prognostic impact of tumour-infiltrating b cells and plasma cells in colorectal cancer. Int J Cancer (2016) 139(5):1129–39. doi: 10.1002/ijc.30138
21
BortolomeazziMKeddarMRMontorsiLAcha-SagredoABenedettiLTemelkovskiDet al. Immunogenomics of colorectal cancer response to checkpoint blockade: Analysis of the KEYNOTE 177 trial and validation cohorts. (2021). Gastroenterology (2021) 161(4):1179–93. doi: 10.1053/j.gastro.2021.06.064
22
ColbeckEJAgerAGallimoreAJonesGW. Tertiary lymphoid structures in cancer: Drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease? Front Immunol (2017) 8:1830. doi: 10.3389/fimmu.2017.01830
23
HelminkBAReddySMGaoJZhangSBasarRThakurRet al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature (2020) 577(7791):549–55. doi: 10.1038/s41586-019-1922-8
24
CabritaRLaussMSannaADoniaMSkaarup LarsenMMitraSet al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature (2020) 577(7791):561–5. doi: 10.1038/s41586-019-1914-8
25
ZaundersJJLévyYSeddikiN. Exploiting differential expression of the IL-7 receptor on memory T cells to modulate immune responses. Cytokine Growth Factor Rev (2014) 25(4):391–401. doi: 10.1016/j.cytogfr.2014.07.012
26
NgiowSFYoungAJacquelotNYamazakiTEnotDZitvogelLet al. A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to anti-PD1. Cancer Res (2015) 75(18):3800–11. doi: 10.1158/0008-5472.CAN-15-1082
27
ShiSJWangLJWangGDGuoZYWeiMMengYLet al. B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PloS One (2013) 8(10):e76012. doi: 10.1371/journal.pone.0076012
28
MarisaLSvrcekMColluraABechtECerveraPWanherdrickKet al. The balance between cytotoxic T-cell lymphocytes and immune checkpoint expression in the prognosis of colon tumors. J Natl Cancer Inst (2018) 110(1):68–77. doi: 10.1093/jnci/djx136
29
BerntssonJEberhardJNodinBLeanderssonKLarssonAHJirströmK. Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis. Oncoimmunology (2018) 7(8):e1465165. doi: 10.1080/2162402X.2018.1465165
30
KamalAMWasfeyEFElghamryWRSabryOMElghobaryHARadwanSM. Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes. Clin Biochem (2021) 96:13–8. doi: 10.1016/j.clinbiochem.2021.06.007
31
LeeSJJunSYLeeIHKangBWParkSYKimHJet al. CD274, LAG3, and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer. J Cancer Res Clin Oncol (2018) 144(6):1005–14. doi: 10.1007/s00432-018-2620-x
32
Rhyner AgocsGAssarzadeganNKirschRDawsonHGalvánJALugliAet al. LAG-3 expression predicts outcome in stage II colon cancer. J Pers Med (2021) 11(8):749. doi: 10.3390/jpm11080749
33
WengJLiSZhuZLiuQZhangRYangYet al. Exploring immunotherapy in colorectal cancer. J Hematol Oncol (2022) 15(1):95. doi: 10.1186/s13045-022-01294-4
34
YinJWangHHongYRenAWangHLiuLet al. Identification of an at-risk subpopulation with high immune infiltration based on the peroxisome pathway and TIM3 in colorectal cancer. BMC Cancer (2022) 22(1):44. doi: 10.1186/s12885-021-09085-9
35
KlapholzMDrageMGSrivastavaAAndersonAC. Presence of Tim3+and PD-1+ CD8+ T cells identifies microsatellite stablecolorectal carcinomas with immune exhaustion and distinct clinicopathological features. J Pathol (2022) 257(2):186–97. doi: 10.1002/path.5877
36
AndersonACJollerNKuchrooVK. Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. Immunity (2016) 44(5):989–1004. doi: 10.1016/j.immuni.2016.05.001
Summary
Keywords
colorectal cancer, nivolumab, ipilimumab, MSI-H, complete pathological response
Citation
Bergamo F, Dalla Santa S, Loupakis F, Cerma K, Tosi A, De Grandis C, Dalla Pietà A, Gringeri E, Angerilli V, Ramondo G, Rago A, Cecchi F, Benz S, Cillo U, Dei Tos AP, Zagonel V, Fassan M, Rosato A and Lonardi S (2022) Case report: Complete pathologic response with first-line immunotherapy combination in a young adult with massive liver dissemination of mismatch repair–deficient metastatic colorectal cancer: Immunological and molecular profiling. Front. Oncol. 12:964219. doi: 10.3389/fonc.2022.964219
Received
08 June 2022
Accepted
04 November 2022
Published
08 December 2022
Volume
12 - 2022
Edited by
Andrea Sartore-Bianchi, University of Milan, Italy
Reviewed by
Michael White, University of Texas MD Anderson Cancer Center, United States; Federica Marmorino, University of Pisa, Italy
Updates
Copyright
© 2022 Bergamo, Dalla Santa, Loupakis, Cerma, Tosi, De Grandis, Dalla Pietà, Gringeri, Angerilli, Ramondo, Rago, Cecchi, Benz, Cillo, Dei Tos, Zagonel, Fassan, Rosato and Lonardi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Sara Lonardi, sara.lonardi@iov.veneto.it
†These authors have contributed equally to this work and share first authorship
‡These authors have contributed equally to this work and share senior authorship
This article was submitted to Gastrointestinal Cancers: Colorectal Cancer, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.